Oncopeptides plans EMA filing to broaden Pepaxti indication

GSK partners with SBP Group to accelerate China launch of bepirovirsen

Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial

Wenda Pharma's oral BET inhibitor NHWD-870 HCI receives Breakthrough Therapy Designation in China in advanced NUT carcinoma

PureHealth Research introduces Berberine-infused natural GLP-1 supplements

Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC

MHRA approves Efmody for adrenal insufficiency treatment

European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis

Rznomics receives FDA RMAT designation for HCC candidate RZ‑001

BioArctic and Eisai report FDA extension of Leqembi Iqlik review

Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD

Chance Pharma reports NMPA acceptance of NDA for investigational respiratory drug CXG87

Altasciences and Certara form strategic partnership to accelerate early drug development

Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma

Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma